← All trials
NCT05851313
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2022
- Primary completion
- Feb 10, 2023
- Completion date
- Apr 7, 2023
- First posted
- May 9, 2023
- Last posted
- May 12, 2023
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sulaimany Polytechnic universityLead sponsor
- Sulaimany Polytechnic universityReponsible party - principal investigator
- Sulaimany Polytechnic universitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.